Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
ViiV Healthcare and GlaxoSmithKline are jointly developing GSK3640254.
“We need drugs that are gentler, kinder, better and cheaper.”
A placebo-controlled Phase IIa study of BMS-955176 has shown that the experimental ARV is potent, safe and well-tolerated.
Research of Bristol-Myers Squibb’s BMS-955176, an HIV maturation inhibitor, has shown the antiretroviral is potent and well-tolerated.
Bristol-Myers Squibb’s investigational next-generation maturation inhibitor BMS-955176 demonstrated good activity against HIV when paired...
Bristol-Myers Squibb’s investigatory maturation inhibitor BMS-955176 showed promise in an early trial examining its potency against HIV.
In the past month, two companies shelved their once-promising experimental HIV drugs, citing the challenging nature of bringing a...
Some disturbing news for treatment-experienced patients holding out for Myriad Genetics’ maturation inhibitor bevirimat: According to a study...
At the XVII International AIDS Conference in Mexico City, David Evanstalks with Andrew Carr, MD, Pro
Vivecon (MPC-9055), a new maturation inhibitor, is moving into early Phase 2 studies. The experimental antiretroviral will be studied in HIV-p...
Professor shares views on the future of HIV treatment and what’s in the pipeline for people with HIV who’ve been on many treatment regimens.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.